Immune Response

Jump to: navigation, search

This page collects observations, interpretations, and consequences for action about Immune Response against SARS-CoV2. Please observe the structure of the page, when you add your content. Please use references where possible. Remember to find the relevant page. For example, if your observation is about Sources, please use that page, instead of posting your content here.

What is already known

Topic 1


  • The IL6 inhibitor Tocilizumab seems to have positive effects in treating COVID19. It has been observed that lymphocytes come back, neutrophils come down. Trials are underway to further study this. [1]
    • The COVID19 is often associated with a cytokine storm that is IL1, IL6, IL10 driven. If you block IL6, then you basically block this entire process. [1]
    • The process of this cytokine storm seems to indicate a maladapted immune response, especially because this is observed after the viral load is already on the way down (day 7-14); this is when the adaptive immune response needs to take over from the innate immune system. Perhaps this is a common mechanism in COVID19, as we see most of the severe deterioration in the period 7-14 days after onset. [1]

Analysis and interpretation

Consequences for action